Viking Therapeutics Q2 Loss Widens to $128M; Cash $502M; Obesity Pipeline Advances

summarizeSummary

Viking Therapeutics reported a wider Q2 2026 net loss of $128 million on surging R&D costs, while advancing its obesity pipeline with fully enrolled Phase 3 trials and upcoming data readouts.

check_boxKey Events · Earnings and Guidance · VKTX

• Q2 Net Loss Widens to $128M

  Net loss of $128.0 million ($1.10/share) vs $65.6 million ($0.58/share) in Q2 2025, driven by R&D expenses of $115.8 million (up from $60.2 million).

• Cash Position Declines to $502M

  Cash, equivalents, and short-term investments fell to $502 million at June 30, 2026, from $706 million at year-end 2025, reflecting heavy clinical trial spending.

• Phase 3 VANQUISH Trials Fully Enrolled

  Both VANQUISH-1 (~4,500 patients) and VANQUISH-2 (~1,000 patients) trials for subcutaneous VK2735 in obesity are fully enrolled and advancing.

• Oral VK2735 Phase 3 Initiation Expected 4Q26

  Company plans to start Phase 3 trials for oral VK2735 in obesity in the fourth quarter of 2026, positioning it as potentially the first oral dual GLP-1/GIP agonist.

auto_awesomeAnalysis · VKTX · Life Sciences

Viking's Q2 net loss more than doubled year-over-year to $128 million as R&D spending surged to $115.8 million, driven by the Phase 3 VANQUISH obesity program. The company ended the quarter with $502 million in cash, down from $706 million at year-end, providing runway but signaling accelerating cash burn. On the pipeline front, both VANQUISH trials are fully enrolled, oral VK2735 Phase 3 is on track for Q4 2026, and maintenance dosing data is due this quarter — milestones that could define the obesity franchise. The appointment of a new chief medical officer adds experienced leadership as the company scales toward potential commercialization.